TrialBlood advances2023
Phase 2 study of PD-1 blockade following autologous transplantation for patients with AML ineligible for allogeneic transplant.
Scott R Solomon et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
9 papers cite it
this papertrialcites it